What it's for (Indications)
- Perindopril + amlodipine, a fixed-dose combination medication, is indicated for the treatment of essential hypertension in adults.
- This combination is particularly suitable for patients whose blood pressure is not adequately controlled with either perindopril or amlodipine monotherapy, or for those who are already receiving perindopril and amlodipine as separate tablets at the same dose levels for comprehensive blood pressure management.
- Beyond its primary role in managing high blood pressure, this medication may also be indicated to reduce the risk of major cardiovascular events, such as myocardial infarction and revascularization procedures, in patients with stable coronary artery disease who are already effectively controlled on individual doses of perindopril and amlodipine.
- The rationale for its use lies in the complementary mechanisms of action of its two components, providing a synergistic approach to cardiovascular risk reduction and blood pressure control.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of perindopril + amlodipine must be carefully individualized based on the patient's clinical response and tolerability to the individual components, perindopril and amlodipine. This fixed-dose combination is typically administered orally, once daily, preferably taken in the morning before a meal to ensure optimal absorption and consistent therapeutic effects. Various strengths are available, commonly including combinations such as perindopril 5 mg / amlodipine 5 mg, perindopril 10 mg / amlodipine 5 mg, perindopril 5 mg / amlodipine 10 mg, and perindopril 10 mg / amlodipine 10 mg. It is generally recommended that patients be stabilized on the individual component doses before transitioning to the fixed combination. For patients with impaired renal function, dosage adjustments may be necessary, and vigilant monitoring of renal function and serum potassium levels is crucial. Similarly, patients with hepatic impairment may require a lower dose of the amlodipine component, necessitating careful clinical assessment and dose titration to avoid adverse effects. |
Safety & Warnings
Common Side Effects
- The side effect profile of perindopril + amlodipine largely reflects the known adverse reactions of its individual components.
- Commonly reported side effects include dizziness, headache, and peripheral edema, particularly swelling of the ankles, which is a hallmark of amlodipine's vasodilatory effects.
- The perindopril component frequently contributes to a persistent, dry cough, and general fatigue.
- Less common but notable adverse reactions can involve gastrointestinal disturbances such as nausea, abdominal pain, and diarrhea.
- Some patients may also experience palpitations or flushing.
- Orthostatic hypotension, characterized by a drop in blood pressure upon standing, may occur, especially at the initiation of therapy or following a dose increase.
- While generally well-tolerated, patients should be encouraged to report any persistent, severe, or concerning side effects to their healthcare provider for appropriate evaluation and management, as some reactions may necessitate dose adjustment or discontinuation.
Serious Warnings
- Black Box Warning: BLACK BOX WARNING: FETAL TOXICITY Perindopril + Amlodipine can cause injury and death to the developing fetus when administered to pregnant women. The use of drugs that act directly on the renin-angiotensin system, such as perindopril, during the second and third trimesters of pregnancy has been associated with severe fetal adverse effects, including fetal hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios, resulting from decreased fetal renal function, has also been reported and may be associated with fetal limb contractures, craniofacial deformation, and lung hypoplasia. These adverse developmental outcomes are generally not associated with exposure to ACE inhibitors during the first trimester. Nevertheless, when pregnancy is detected, perindopril + amlodipine should be discontinued as soon as possible. Healthcare providers should inform female patients of childbearing potential about the potential risks to the fetus if they become pregnant while taking this medication and advise them to contact their physician immediately if pregnancy is suspected. If pregnancy is confirmed, alternative antihypertensive treatments with a more favorable pregnancy safety profile should be initiated without delay.
- Several important warnings are associated with the use of perindopril + amlodipine.
- The perindopril component, an ACE inhibitor, carries a significant risk of angioedema, which can manifest as swelling of the face, extremities, lips, tongue, glottis, and/or larynx, and can be life-threatening if airway obstruction occurs.
- Immediate medical intervention is required for any signs of angioedema.
- Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk.
- Hyperkalemia (elevated serum potassium levels) is another serious concern, especially in patients with pre-existing renal impairment, diabetes mellitus, or those concurrently taking potassium-sparing diuretics, potassium supplements, or other medications that can increase potassium.
- Symptomatic hypotension, particularly a pronounced drop in blood pressure with the first dose or in volume-depleted individuals, can occur.
- The amlodipine component, though generally well-tolerated, has rarely been associated with worsening angina or acute myocardial infarction upon initiation or dose escalation, particularly in patients with severe underlying obstructive coronary artery disease.
- Use in patients with severe hepatic impairment requires extreme caution and careful dose adjustment due to the potential for amlodipine accumulation.
- Regular monitoring of renal function, electrolytes, and blood pressure is imperative during treatment.
How it Works (Mechanism of Action)
Perindopril + amlodipine combines two potent antihypertensive agents with distinct yet complementary mechanisms of action to achieve comprehensive blood pressure control and cardiovascular benefits. Perindopril is an angiotensin-converting enzyme (ACE) inhibitor. It acts by blocking the conversion of angiotensin I to angiotensin II, a powerful vasoconstrictor and stimulator of aldosterone secretion. By inhibiting ACE, perindopril reduces systemic vascular resistance, lowers blood pressure, decreases aldosterone-mediated sodium and water retention, and diminishes sympathetic nervous system activity. Additionally, it reduces the degradation of bradykinin, a vasodilatory peptide, further contributing to its blood pressure-lowering effects. Amlodipine, a dihydropyridine calcium channel blocker, selectively inhibits the transmembrane influx of calcium ions into vascular smooth muscle and, to a lesser extent, cardiac muscle cells. This action primarily results in peripheral arterial vasodilation, thereby reducing total peripheral resistance and blood pressure. Its vasodilatory effects also contribute to improved myocardial oxygen supply in patients with angina. The combination of these two agents provides a multifaceted approach to managing hypertension, addressing both the renin-angiotensin-aldosterone system and vascular tone, leading to synergistic therapeutic effects.